Elo Mutual Pension Insurance Co Increases Holdings in Becton, Dickinson and Company $BDX

Elo Mutual Pension Insurance Co increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 24.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,609 shares of the medical instruments supplier’s stock after purchasing an additional 6,856 shares during the quarter. Elo Mutual Pension Insurance Co’s holdings in Becton, Dickinson and Company were worth $6,478,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares during the last quarter. RiverGlades Family Offices LLC purchased a new stake in shares of Becton, Dickinson and Company in the second quarter worth about $344,000. Oppenheimer Asset Management Inc. boosted its stake in Becton, Dickinson and Company by 71.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier’s stock valued at $15,471,000 after buying an additional 34,437 shares during the last quarter. Transcend Capital Advisors LLC grew its holdings in Becton, Dickinson and Company by 88.2% during the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier’s stock valued at $1,084,000 after buying an additional 2,715 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $650,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Stock Up 0.1%

Shares of NYSE BDX opened at $176.68 on Tuesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The company has a market cap of $50.31 billion, a P/E ratio of 28.82, a PEG ratio of 12.79 and a beta of 0.24. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35. The firm has a 50-day simple moving average of $195.28 and a two-hundred day simple moving average of $191.90.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The firm had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same quarter in the prior year, the firm posted $3.43 earnings per share. The company’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 68.52%.

Becton, Dickinson and Company declared that its board has approved a stock repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its stock is undervalued.

Analyst Upgrades and Downgrades

BDX has been the subject of a number of recent research reports. Zacks Research lowered shares of Becton, Dickinson and Company from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 11th. Barclays assumed coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. They issued an “overweight” rating and a $202.00 price objective for the company. Jefferies Financial Group decreased their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. Citigroup dropped their price target on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating for the company in a research report on Tuesday, February 10th. Finally, TD Cowen upped their price objective on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $195.46.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bertram L. Scott sold 953 shares of the firm’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at approximately $6,713,291.43. This trade represents a 2.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 3,416 shares of company stock valued at $674,693 over the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.